Related Experiment Videos
[Gastric carcinoid--pathogenesis and treatment]
R Bründler1, J O Gebbers, D Criblez
1Pathologisches Institut, Kantonsspital Luzern.
Schweizerische Medizinische Wochenschrift
|July 28, 1999
Summary
Gastric carcinoid tumors, rare neuroendocrine neoplasms, arise from ECL cells. Management varies by type: hypergastrinaemic (Type I & II) or sporadic (Type III), with surgery often avoidable for benign hypergastrinaemic forms.
Area of Science:
- Gastroenterology
- Oncology
- Endocrinology
Context:
- Gastric carcinoid tumors are rare neuroendocrine neoplasms originating from enterochrommaffin-like (ECL) cells.
- Three distinct types are recognized: Type I (hypergastrinaemic, associated with chronic atrophic gastritis), Type II (hypergastrinaemic, linked to Zollinger-Ellison syndrome and MEN1), and Type III (sporadic).
Purpose:
- To discuss the pathogenesis and management strategies for the three types of gastric carcinoid tumors.
- To highlight the critical role of gastrin's trophic effect on ECL cells in hypergastrinaemic carcinoids.
Summary:
- Gastrin's trophic effect drives ECL cell hyperplasia, dysplasia, and neoplasia in hypergastrinaemic carcinoids.
- These tumors, particularly hypergastrinaemic types, often exhibit a benign clinical course.
- Management approaches are tailored to each type, with non-surgical options considered for high-risk patients.
Impact:
- Provides a framework for understanding the classification and progression of gastric carcinoid tumors.
- Informs clinical decision-making regarding the management of hypergastrinaemic and sporadic gastric carcinoids.
- Emphasizes the potential for conservative management in select patient populations, avoiding surgical risks.